These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
174 related articles for article (PubMed ID: 6407285)
21. An open study with reversible MAO-A inhibitors in complicated Parkinson's disease. Ruggieri S; Fabbrini G; Bramante L; DePandis F; Stocchi F; Barbanti P; Vacca L; Manfredi M Adv Neurol; 1996; 69():595-8. PubMed ID: 8615185 [No Abstract] [Full Text] [Related]
22. Selegiline orally disintegrating tablets for the treatment of Parkinson's disease. Lew MF Expert Rev Neurother; 2005 Nov; 5(6):705-12. PubMed ID: 16274328 [TBL] [Abstract][Full Text] [Related]
23. DATATOP-study: significance of its results in the treatment of Parkinson's disease. Schneider E J Neural Transm Suppl; 1995; 46():391-7. PubMed ID: 8821074 [TBL] [Abstract][Full Text] [Related]
24. Combined and selective monoamine oxidase inhibition in the treatment of depression in Parkinson's disease. Jansen Steur EN; Ballering LA Adv Neurol; 1999; 80():505-8. PubMed ID: 10410764 [No Abstract] [Full Text] [Related]
34. Adjuvant drugs in the treatment of on-off phenomena in Parkinson's disease. Csanda E; Tárczy M; Takáts A; Mogyorós I; Köves A; Bihari K Adv Neurol; 1984; 40():549-56. PubMed ID: 6421113 [No Abstract] [Full Text] [Related]
35. [Use of iumeks in the combined therapy of parkinsonism patients ]. Man'kovskiĭ NB; Karaban' IN; Mialovitskaia EA Vrach Delo; 1987 Aug; (8):100-2. PubMed ID: 3120415 [No Abstract] [Full Text] [Related]
36. New mechanisms of action of irreversible monoamine oxidase type B inhibitors. Li XM; Juorio AV; Paterson IA; Boulton AA J Psychiatry Neurosci; 1993 Jul; 18(4):199-200. PubMed ID: 8373757 [No Abstract] [Full Text] [Related]
37. Elucidating the mechanism of action and potential interactions of MAO-B inhibitors. Bainbridge JL; Page RL; Ruscin JM Neurol Clin; 2008 Aug; 26(3 Suppl):S85-96, vi. PubMed ID: 18774444 [TBL] [Abstract][Full Text] [Related]
38. [On the treatment of Parkinson's syndrome with monoamine oxidase inhibitors alone and in combination with L-dopa]. Gerstenbrand F; Prosenz P Praxis; 1965 Nov; 54(46):1373-7. PubMed ID: 5899418 [No Abstract] [Full Text] [Related]
39. The relevance of glial monoamine oxidase-B and polyamines to the action of selegiline in Parkinson's disease. Youdim MB; Riederer P Mov Disord; 1993; 8 Suppl 1():S8-13. PubMed ID: 8302308 [TBL] [Abstract][Full Text] [Related]
40. Clinical pharmacology of MAO inhibitors: safety and future. Yamada M; Yasuhara H Neurotoxicology; 2004 Jan; 25(1-2):215-21. PubMed ID: 14697896 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]